Document Detail


Fluconazole pharmacokinetics and safety in premature infants.
MedLine Citation:
PMID:  22876898     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating its pharmacokinetics (PK) and safety have been performed in this vulnerable population. We review five phase I studies examining the PK of fluconazole in premature infants, which demonstrate markedly differing kinetics compared to adults. Based on these data, a treatment dose of 12 mg/kg/day, with the potential need of a loading dose of 25 mg/kg to achieve rapid steady state concentrations, achieves surrogate pharmacodynamic targets. Additionally, fluconazole appears to be safe to use in this population, with only minimal reversible hepatobiliary effects.
Authors:
K Turner; P Manzoni; D K Benjamin; M Cohen-Wolkowiez; P B Smith; M M Laughon
Related Documents :
8903898 - Neonatal chronic lung disease, oxygen dependency, and a family history of asthma.
20955848 - Regional oxygen saturation of the brain and peripheral tissue during birth transition o...
9521968 - The collaborative uk ecmo (extracorporeal membrane oxygenation) trial: follow-up to 1 y...
9266198 - Response to nitric oxide in term and preterm infants.
4958618 - Monkeys reared in isolation with pictures as visual input: evidence for an innate relea...
1327928 - Suspect value of non-csf viral cultures in the diagnosis of enteroviral cns infection i...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current medicinal chemistry     Volume:  19     ISSN:  1875-533X     ISO Abbreviation:  Curr. Med. Chem.     Publication Date:  2012  
Date Detail:
Created Date:  2012-10-24     Completed Date:  2013-03-21     Revised Date:  2014-04-28    
Medline Journal Info:
Nlm Unique ID:  9440157     Medline TA:  Curr Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  4617-20     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antifungal Agents / pharmacokinetics,  therapeutic use
Candidiasis, Invasive / drug therapy
Clinical Trials as Topic
Fluconazole / pharmacokinetics*,  therapeutic use
Half-Life
Humans
Infant, Newborn
Infant, Premature
Grant Support
ID/Acronym/Agency:
HHSN267200700051C/HD/NICHD NIH HHS; K23 HD060040/HD/NICHD NIH HHS; K23 HD068497/HD/NICHD NIH HHS; K24 HD058735/HD/NICHD NIH HHS; R01 FD003519/FD/FDA HHS; R01 HD057956/HD/NICHD NIH HHS; T32 GM086330/GM/NIGMS NIH HHS; U10 HD045962/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Antifungal Agents; 8VZV102JFY/Fluconazole
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Drugs in newborn resuscitation: the more we learn the least we use.
Next Document:  Pharmacokinetics of Antifungal Agents in Neonates and Young Infants.